| 4.2 -0.06 (-1.41%) | 06-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.99 | 1-year : | 8.52 |
| Resists | First : | 5.99 | Second : | 7.3 |
| Pivot price | 4.71  |
|||
| Supports | First : | 3.87 | Second : | 3.22 |
| MAs | MA(5) : | 4.09 | MA(20) : | 4.94 |
| MA(100) : | 5.95 |
MA(250) : | 10.2 |
|
| MACD | MACD : | -0.5  |
Signal : | -0.5 |
| %K %D | K(14,3) : | 12.2 |
D(3) : | 8.6 |
| RSI | RSI(14): 34.5 |
|||
| 52-week | High : | 23.5 | Low : | 2.9 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PSTV ] has closed above bottom band by 28.4%. Bollinger Bands are 7.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.46 - 4.48 | 4.48 - 4.5 |
| Low: | 4.07 - 4.1 | 4.1 - 4.12 |
| Close: | 4.16 - 4.2 | 4.2 - 4.24 |
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.
Thu, 25 Jun 2026
Plus Therapeutics, Inc. Actuals & Estimates (NASDAQ:PSTV) - TradingView
Thu, 25 Jun 2026
Plus Therapeutics wins Elevance Health coverage deal - Seeking Alpha
Thu, 25 Jun 2026
Plus Therapeutics gets national health coverage for CNS cancer test - Stock Titan
Wed, 24 Jun 2026
Plus Therapeutics to Provide Business Update Call on June 30, 2026 - Sahm
Tue, 23 Jun 2026
Plus Therapeutics to detail CNSide launch, Reyobiq plan June 30 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 10.3 (%) |
| Shares Short | 1,140 (K) |
| Shares Short P.Month | 1,230 (K) |
| EPS | 21.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.74 |
| Profit Margin | -230.3 % |
| Operating Margin | -692.6 % |
| Return on Assets (ttm) | -73.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -3 % |
| Gross Profit (p.s.) | -0.63 |
| Sales Per Share | 0.75 |
| EBITDA (p.s.) | -2.69 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | 0.19 |
| PEG Ratio | 2.4 |
| Price to Book value | 2.41 |
| Price to Sales | 5.57 |
| Price to Cash Flow | -1.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|